52530073,,459971,21435029,,18528853,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530074,,459971,21435062,,18528902,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530075,,459971,21435076,,18528921,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530076,,459971,21434971,,18528774,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530077,,459971,21435048,,18528883,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530078,,459971,21434986,,18528792,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530079,,459971,21435064,,18528905,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530080,,459971,21435031,,18528859,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530081,,459971,21434980,,18528783,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530082,,459971,21434995,,18528805,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530083,,459971,21435102,,18528961,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530084,,459971,21435120,,18528997,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530085,,459971,21435046,,18528880,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530086,,459971,21434996,,18528806,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530087,,459971,21434964,,18528761,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530088,,459971,21434994,,18528801,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530089,,459971,21435002,,18528815,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530090,,459971,21435007,,18528823,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530091,,459971,21435094,,18528947,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530092,,459971,21435126,,18529008,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530093,,459971,21435081,,18528927,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530094,,459971,21434990,,18528796,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530095,,459971,21434981,,18528784,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530096,,459971,21435085,,18528934,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530097,,459971,21435099,,18528955,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530098,,459971,21435121,,18528998,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530099,,459971,21434991,,18528798,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530100,,459971,21435020,,18528840,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530101,,459971,21435041,,18528875,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530102,,459971,21434993,,18528800,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530103,,459971,21435044,,18528878,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530104,,459971,21435089,,18528940,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530105,,459971,21435124,,18529005,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530106,,459971,21434982,,18528786,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530107,,459971,21434992,,18528799,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530108,,459971,21435004,,18528819,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530109,,459971,21435056,,18528892,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530110,,459971,21435050,,18528885,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530111,,459971,21435051,,18528886,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530112,,459971,21435104,,18528964,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530113,,459971,21435109,,18528972,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530114,,459971,21435138,,18529034,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530115,,459971,21434965,,18528763,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530116,,459971,21435058,,18528894,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530117,,459971,21435147,,18529056,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530118,,459971,21435134,,18529027,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530119,,459971,21434963,,18528758,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530120,,459971,21435040,,18528874,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530121,,459971,21435077,,18528922,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530122,,459971,21435075,,18528920,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530123,,459971,21435049,,18528884,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530124,,459971,21435132,,18529019,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530125,,459971,21435137,,18529032,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530126,,459971,21434985,,18528791,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530127,,459971,21435042,,18528876,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530128,,459971,21435036,,18528870,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530129,,459971,21435009,,18528825,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530130,,459971,21435010,,18528826,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530131,,459971,21435069,,18528912,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530132,,459971,21435080,,18528925,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530133,,459971,21435045,,18528879,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530134,,459971,21435095,,18528948,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530135,,459971,21435145,,18529048,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530136,,459971,21435057,,18528893,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530137,,459971,21435097,,18528951,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530138,,459971,21435024,,18528845,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530139,,459971,21435152,,18529076,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530140,,459971,21435149,,18529061,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530141,,459971,21435053,,18528888,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530142,,459971,21435148,,18529060,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530143,,459971,21435139,,18529035,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530144,,459971,21434970,,18528772,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530145,,459971,21434966,,18528764,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530146,,459971,21435067,,18528910,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530147,,459971,21435133,,18529025,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530148,,459971,21435125,,18529006,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530149,,459971,21434977,,18528780,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530150,,459971,21435135,,18529029,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530151,,459971,21435059,,18528895,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530152,,459971,21435091,,18528942,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530153,,459971,21435021,,18528841,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530154,,459971,21435154,,25035954,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530155,,459971,21435022,,18528843,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530156,,459971,21435018,,18528837,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530157,,459971,21435155,,25035956,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530158,,459971,21435129,,18529016,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530159,,459971,21435082,,18528930,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530160,,459971,21435066,,18528909,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530161,,459971,21434969,,18528771,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530162,,459971,21434976,,18528779,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530163,,459971,21435071,,18528914,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530164,,459971,21435015,,18528834,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530165,,459971,21434962,,18528756,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530166,,459971,21434961,,18528755,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530167,,459971,21435023,,18528844,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530168,,459971,21434978,,18528781,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530169,,459971,21435078,,18528923,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530170,,459971,21435027,,18528850,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530171,,459971,21435105,,18528966,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530172,,459971,21435156,,25035960,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530173,,459971,21435033,,18528865,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530174,,459971,21435144,,18529044,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530175,,459971,21434984,,18528789,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530176,,459971,21435118,,18528994,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530177,,459971,21435142,,18529040,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530178,,459971,21435157,,25035962,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530179,,459971,21434968,,18528767,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530180,,459971,21435079,,18528924,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530181,,459971,21435025,,18528846,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530182,,459971,21435158,,25035965,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530183,,459971,21435001,,18528813,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530184,,459971,21435032,,18528861,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530185,,459971,21435150,,18529070,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530186,,459971,21435026,,18528848,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530187,,459971,21435159,,25035969,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530188,,459971,21435096,,18528950,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530189,,459971,21435083,,18528932,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530190,,459971,21434983,,18528788,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530191,,459971,21435047,,18528882,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530192,,459971,21435014,,18528831,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530193,,459971,21434975,,18528778,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530194,,459971,21434973,,18528776,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530195,,459971,21435107,,18528968,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530196,,459971,21435063,,18528904,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530197,,459971,21435072,,18528916,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530198,,459971,21435119,,18528996,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530199,,459971,21435092,,18528944,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530200,,459971,21435000,,18528811,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530201,,459971,21435012,,18528828,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530202,,459971,21435128,,18529015,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530203,,459971,21435136,,18529031,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530204,,459971,21435110,,18528973,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530205,,459971,21435117,,18528991,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530206,,459971,21435006,,18528822,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530207,,459971,21435140,,18529037,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530208,,459971,21435065,,18528907,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530209,,459971,21435111,,18528974,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530210,,459971,21435123,,18529004,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530211,,459971,21435101,,18528960,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530212,,459971,21435013,,18528829,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530213,,459971,21434972,,18528775,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530214,,459971,21435011,,18528827,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530215,,459971,21434987,,18528793,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530216,,459971,21435003,,18528818,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530217,,459971,21434988,,18528794,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530218,,459971,21435043,,18528877,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530219,,459971,21435106,,18528967,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530220,,459971,21435087,,18528937,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530221,,459971,21435114,,18528979,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530222,,459971,21435098,,18528953,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530223,,459971,21435005,,18528820,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530224,,459971,21435127,,18529013,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530225,,459971,21435074,,18528919,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530226,,459971,21435116,,18528983,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530227,,459971,21435088,,18528939,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530228,,459971,21435115,,18528980,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530229,,459971,21435039,,18528873,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530230,,459971,21435037,,18528871,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530231,,459971,21435070,,18528913,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530232,,459971,21435073,,18528918,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530233,,459971,21435112,,18528976,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530234,,459971,21435130,,18529017,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530235,,459971,21435019,,18528839,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530236,,459971,21435113,,18528977,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530237,,459971,21435038,,18528872,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530238,,459971,21435017,,18528836,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530239,,459971,21435108,,18528969,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530240,,459971,21435143,,18529042,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530241,,459971,21435151,,18529071,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530242,,459971,21434999,,18528809,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530243,,459971,21434974,,18528777,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530244,,459971,21435131,,18529018,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530245,,459971,21435146,,18529051,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530246,,459971,21435093,,18528946,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530247,,459971,21435084,,18528933,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530248,,459971,21435068,,18528911,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530249,,459971,21435090,,18528941,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530250,,459971,21435141,,18529039,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530251,,459971,21435034,,18528866,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530252,,459971,21435054,,18528889,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530253,,459971,21435060,,18528897,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530254,,459971,21435086,,18528936,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530255,,459971,21435055,,18528891,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530256,,459971,21435160,,25035987,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530257,,459971,21434989,,18528795,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530258,,459971,21435103,,18528962,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530259,,459971,21435153,,24265202,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530260,,459971,21435028,,18528851,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530261,,459971,21434998,,18528808,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530262,,459971,21435122,,18529001,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530263,,459971,21435016,,18528835,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530264,,459971,21435035,,18528868,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530265,,459971,21435008,,18528824,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530266,,459971,21434997,,18528807,,,,,,,,,7168429,IC50,,6089319,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration of the compound against ligand-induced autophosphorylation at Y223 of Bruton's tyrosine kinase (BTK) from human in Ramos cells upon incubation for 1 hour,,1806776,Ramos cell line,,,,human,3844655,,Tyrosine-protein kinase BTK [human],human,Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human]:Wild,Tyrosine-protein kinase BTK [human],,,human,,,,=,10,,µM,5,result normalized in M; pAur = -log(value),,,,2018/11/16,Tyrosine-protein kinase BTK [human],1,2020/03/17,
52530267,,7786306,21435163,MAIN,1903159,,,,,,,,,7168432,qualitative,,6089322,,,In Vivo (Animal models),,,,,,,,,,,,,,,,,,,,,,,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530268,,7784781,21435164,MAIN,17092504,,,,,,,,,7121731,qualitative,,6046137,,,In Vivo (Animal models),,,,,,,,,,,,,,,,,,,,,,,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530269,,61995009,21435189,MAIN,18653990,Pyrimidinone1,,,,,,,,7168434,EC50,,6089324,cAMP production,Second messenger,In Vitro (Efficacy),,,Agonist,,,1806777,HEK293 cell line,,,,,3844659,,Glucose-dependent insulinotropic receptor [human],human,Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human],Target,Transfected,,,,,~,50 - 14000,,nM,7.3,result normalized in M; pAur = -log(value),,,,2018/11/16,Glucose-dependent insulinotropic receptor [human],,2020/03/17,
52530270,,61995009,21435191,MAIN,18654045,Pyrimidinone284,,,,,,,,7168434,EC50,,6089324,cAMP production,Second messenger,In Vitro (Efficacy),,,Agonist,,,1806777,HEK293 cell line,,,,,3844659,,Glucose-dependent insulinotropic receptor [human],human,Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human],Target,Transfected,,,,,~,50 - 14000,,nM,7.3,result normalized in M; pAur = -log(value),,,,2018/11/16,Glucose-dependent insulinotropic receptor [human],,2020/03/17,
52530271,,61995009,21435190,MAIN,18654005,Pyrimidinone292,,,,,,,,7168434,EC50,,6089324,cAMP production,Second messenger,In Vitro (Efficacy),,,Agonist,,,1806777,HEK293 cell line,,,,,3844659,,Glucose-dependent insulinotropic receptor [human],human,Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human],Target,Transfected,,,,,~,50 - 14000,,nM,7.3,result normalized in M; pAur = -log(value),,,,2018/11/16,Glucose-dependent insulinotropic receptor [human],,2020/03/17,
52530272,,61995009,21435188,MAIN,18653984,Pyrimidinone165,,,,,,,,7168434,EC50,,6089324,cAMP production,Second messenger,In Vitro (Efficacy),,,Agonist,,,1806777,HEK293 cell line,,,,,3844659,,Glucose-dependent insulinotropic receptor [human],human,Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human],Target,Transfected,,,,,~,50 - 14000,,nM,7.3,result normalized in M; pAur = -log(value),,,,2018/11/16,Glucose-dependent insulinotropic receptor [human],,2020/03/17,
52530273,,61995009,21435187,MAIN,18653926,Pyrimidinone300,,,,,,,,7168434,EC50,,6089324,cAMP production,Second messenger,In Vitro (Efficacy),,,Agonist,,,1806777,HEK293 cell line,,,,,3844659,,Glucose-dependent insulinotropic receptor [human],human,Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human],Target,Transfected,,,,,~,50 - 14000,,nM,7.3,result normalized in M; pAur = -log(value),,,,2018/11/16,Glucose-dependent insulinotropic receptor [human],,2020/03/17,
52530274,,61995009,21435186,MAIN,18653897,Pyrimidinone10,,,,,,,,7168434,EC50,,6089324,cAMP production,Second messenger,In Vitro (Efficacy),,,Agonist,,,1806777,HEK293 cell line,,,,,3844659,,Glucose-dependent insulinotropic receptor [human],human,Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human],Target,Transfected,,,,,~,50 - 14000,,nM,7.3,result normalized in M; pAur = -log(value),,,,2018/11/16,Glucose-dependent insulinotropic receptor [human],,2020/03/17,
52530275,,61995009,21435183,MAIN,18653758,Pyrimidinone31,,,,,,,,7168434,EC50,,6089324,cAMP production,Second messenger,In Vitro (Efficacy),,,Agonist,,,1806777,HEK293 cell line,,,,,3844659,,Glucose-dependent insulinotropic receptor [human],human,Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human],Target,Transfected,,,,,~,50 - 14000,,nM,7.3,result normalized in M; pAur = -log(value),,,,2018/11/16,Glucose-dependent insulinotropic receptor [human],,2020/03/17,
52530276,,61995009,21435185,MAIN,18653812,Pyrimidinone35,,,,,,,,7168434,EC50,,6089324,cAMP production,Second messenger,In Vitro (Efficacy),,,Agonist,,,1806777,HEK293 cell line,,,,,3844659,,Glucose-dependent insulinotropic receptor [human],human,Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human],Target,Transfected,,,,,~,50 - 14000,,nM,7.3,result normalized in M; pAur = -log(value),,,,2018/11/16,Glucose-dependent insulinotropic receptor [human],,2020/03/17,
52530277,,61995009,21435192,MAIN,18654060,Pyrimidinone344,,,,,,,,7168434,EC50,,6089324,cAMP production,Second messenger,In Vitro (Efficacy),,,Agonist,,,1806777,HEK293 cell line,,,,,3844659,,Glucose-dependent insulinotropic receptor [human],human,Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human],Target,Transfected,,,,,~,50 - 14000,,nM,7.3,result normalized in M; pAur = -log(value),,,,2018/11/16,Glucose-dependent insulinotropic receptor [human],,2020/03/17,
52530278,,61995009,21435184,MAIN,18653785,Pyrimidinone338,,,,,,,,7168434,EC50,,6089324,cAMP production,Second messenger,In Vitro (Efficacy),,,Agonist,,,1806777,HEK293 cell line,,,,,3844659,,Glucose-dependent insulinotropic receptor [human],human,Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human]:Wild,Glucose-dependent insulinotropic receptor [human],Target,Transfected,,,,,~,50 - 14000,,nM,7.3,result normalized in M; pAur = -log(value),,,,2018/11/16,Glucose-dependent insulinotropic receptor [human],,2020/03/17,
52530280,,61995009,21435165,,21514424,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530282,,61995009,21435179,,25380705,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530284,,61995009,21435180,,25380709,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530285,,61995009,21435178,,21543916,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530286,,61995009,21435177,,21543890,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530288,,61995009,21435181,,25380714,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530290,,61995009,21435175,,21514450,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530292,,61995009,21435173,,21514439,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530293,,61995009,21435172,,21514438,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530294,,61995009,21435167,,21514426,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530295,,61995009,21435168,,21514428,,,,,,,,,7168433,IC50,,6089323,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory concentration against Interleukin-1 receptor-associated kinase 4 in presence of ATP (10 uM) upon incubation at RT for 30 min in 50 mM HEPES buffer using TR-FRET assay with compound dissolved in (1) DMSO,,1806778,,,,,,3844658,,Interleukin-1 receptor-associated kinase 4,,Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4:Wild,Interleukin-1 receptor-associated kinase 4,,,,,,,<,20,,µM,4.7,result normalized in M; pAur = -log(value),,,,2018/11/16,Interleukin-1 receptor-associated kinase 4,1,2020/03/17,
52530296,,379181,21435197,MAIN,2197934,1459143,,,,,,,,7168435,qualitative,,6089325,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : spermicidal,spermicidal agent,1806779,spermatozoon,,,,rat,,,,,,,,,,,rat,,,"for title compound motility of sperm was 0-80 % and more, viability-0 or not done; title compound showed spermicidal effect in dose- and time-dependent manner",,,,,,,,,,2018/11/16,,,2018/11/22,
52530297,,385065,21435210,MAIN,8188049,,intraduodenal administration,,,,,,,7168436,qualitative,,6089328,,,In Vivo (Animal models),,,,biovailability,,1806780,,,,,Sprague Dawley rat,,,,,,,,,,,Sprague Dawley rat,,,"intraduodenal administration of title compound exhibited dose dependent serum plasma concentration profile when carrier amount was fixed, small amounts of carrier (10-20 units) exhibited increased absorption of title compound compared to higher dosages of carrier, carrier containing polyL-lysine and sucrose laurate 16 showed increased absorption compared to carrier containing glucosamine and sucrose laurate 16 based on calculated availabilities of 21.3 and 6.6, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530298,,385065,21435209,MAIN,8188049,,subcutaneous administration,,,,,,,7168436,qualitative,,6089328,,,In Vivo (Animal models),,,,biovailability,,1806780,,,,,Sprague Dawley rat,,,,,,,,,,,Sprague Dawley rat,,,subcutaneous administration of title compound exhibited dose dependent serum plasma concentration profile,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530299,,385065,21435208,MAIN,18527350,,intraduodenal administration,,,,,,,7168436,qualitative,,6089328,,,In Vivo (Animal models),,,,biovailability,,1806780,,,,,Sprague Dawley rat,,,,,,,,,,,Sprague Dawley rat,,,time dependent changes in the plasma concentration of recombinant human growth hormone (0 to 197.2 ng/ml) were observed 10-90 min after administration of title compound,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530300,,385065,21435207,MAIN,18527349,,intraduodenal administration,,,,,,,7168436,qualitative,,6089328,,,In Vivo (Animal models),,,,biovailability,,1806780,,,,,Sprague Dawley rat,,,,,,,,,,,Sprague Dawley rat,,,time dependent changes in the plasma concentration of recombinant human growth hormone (253.28 to 376.47 ng/ml) were observed 10-90 min after administration of title compound,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530301,,385065,21435203,MAIN,18527345,,intraduodenal administration,,,,,,,7168437,qualitative,,6089327,,,In Vivo (Animal models),,,,biovailability,,1806781,,,,,rat,,,,,,,,,,,rat,,,time dependent changes in the plasma concentration of aztreonam (55.24 to 96.99 ug/ml) were observed 30-240 min after administration of title compound; bioavailability: 91.1,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530302,,385065,21435202,MAIN,18527344,,intraduodenal administration,,,,,,,7168437,qualitative,,6089327,,,In Vivo (Animal models),,,,biovailability,,1806781,,,,,rat,,,,,,,,,,,rat,,,time dependent changes in the plasma concentration of calcitonin (0.69 to 10.955 ng/ml) were observed 10-240 min after administration of title compound,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530303,,385065,21435200,MAIN,18527342,,intraduodenal administration,,,,,,,7168437,qualitative,,6089327,,,In Vivo (Animal models),,,,biovailability,,1806781,,,,,rat,,,,,,,,,,,rat,,,time dependent changes in the plasma concentration of catechin (32.16 to 65.94 ug/ml) were observed 15-180 min after administration of title compound,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530304,,385065,21435205,MAIN,18527347,,intraduodenal administration,,,,,,,7168437,qualitative,,6089327,,,In Vivo (Animal models),,,,biovailability,,1806781,,,,,rat,,,,,,,,,,,rat,,,time dependent changes in the plasma concentration of isepamicin (35.75 to 101.78 ug/ml) were observed 30-360 min after administration of title compound,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530305,,385065,21435204,MAIN,18527346,,intraduodenal administration,,,,,,,7168437,qualitative,,6089327,,,In Vivo (Animal models),,,,biovailability,,1806781,,,,,rat,,,,,,,,,,,rat,,,time dependent changes in the plasma concentration of netilmicin (34.79 to 70.74 ug/ml) were observed 30-360 min after administration of title compound; bioavailability: 73.05,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530306,,385065,21435199,MAIN,18527341,,intraduodenal administration,,,,,,,7168437,qualitative,,6089327,,,In Vivo (Animal models),,,,biovailability,,1806781,,,,,rat,,,,,,,,,,,rat,,,time dependent changes in the plasma concentration of paclitaxel (0.61 to 4.14 ug/ml) were observed 5-180 min after administration of title compound; bioavailability: 21.3,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530307,,385065,21435198,MAIN,18527340,,intraduodenal administration,,,,,,,7168437,qualitative,,6089327,,,In Vivo (Animal models),,,,biovailability,,1806781,,,,,rat,,,,,,,,,,,rat,,,time dependent changes in the plasma concentration of paclitaxel (1.50 to 4.46 ug/ml) were observed 5-180 min after administration of title compound; bioavailability: 20.7,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530308,,385065,21435206,MAIN,18527348,,intraduodenal administration,,,,,,,7168437,qualitative,,6089327,,,In Vivo (Animal models),,,,biovailability,,1806781,,,,,rat,,,,,,,,,,,rat,,,time dependent changes in the plasma concentration of teicoplanin  (9.50 to 12.22 ug/ml) were observed 30-240 min after administration of title compound; bioavailability: 35.07,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530309,,385065,21435201,MAIN,18527343,,intraduodenal administration,,,,,,,7168438,qualitative,,6089326,,,In Vivo (Animal models),,,,biovailability,,,,,,,,,,,,,,,,,,,,,"in diabetic rats serum insulin was detected in blood and significant hypoglycemic effects were observed following administration of title substance, no significant hypoglycemic response was registered in non-diabetic rats",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530310,,381034,21435212,MAIN,779271,34524,,,,Marketed,,,,7168441,qualitative,,6089331,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : cytoprotective,cytoprotective agent,1806785,keratinocyte,,,,human,,,,,,,,,,,human,,,title compound at 0.03% protected cells from UVB toxicity as evidenced by decrease in irradiation-induced lactate dehydrogenase (LDH) and prostaglandin E2 (PGE2) release,,,,,,,,,,2018/11/16,,,2018/11/22,
52530311,,381034,21435213,MAIN,94012,1418457,,,,Marketed,,,,7168439,qualitative,,6089329,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : cytoprotective,cytoprotective agent,1806783,fibroblast,,,,human,,,,,,,,,,,human,,,title compound at 0.0003% protected cells from UVA toxicity as evidenced by decrease in irradiation-induced malonaldialdehyde (MDA) release,,,,,,,,,,2018/11/16,,,2018/11/22,
52530312,,381034,21435211,MAIN,120895,463584,,,,,,,,7168440,qualitative,,6089330,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : melanin synthesis; inhibition of  ,,1806786,B16 cell line,,,,human,,,,,,,,,,,human,,,title compound at 0.03% inhibted melanin synthesis (34% versus 100% in control),,,,,,,,,,2018/11/16,,,2018/11/22,
52530313,,381034,21435216,MAIN,18526918,,,,,,,,,7168442,qualitative,,6089335,,,In Vitro (Efficacy),,,,cytoprotective,cytoprotective agent,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,title compound at 0.1 or 0.3 protected cells from UVA toxicity as evidenced by decrease in irradiation-induced malonaldialdehyde (MDA) release,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530314,,381034,21435216,MAIN,18526918,,,,,,,,,7168443,qualitative,,6089336,,,In Vitro (Efficacy),,,,cytoprotective,cytoprotective agent,1806784,keratinocyte,,,,human,,,,,,,,,,,human,,,title compound at 0.1 or 0.3 protected cells from UVB toxicity as evidenced by decrease in irradiation-induced lactate dehydrogenase (LDH) and prostaglandin E2 (PGE2) release,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530315,,381034,21435217,MAIN,18526919,,,,,,,,,7168444,qualitative,,6089332,,,In Vitro (Efficacy),,,,DNA levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.03 or 0.1 increased cell adenosine triphosphate (ATP) levels up to 109 or 111 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530316,,381034,21435214,MAIN,33586252,,,,,,,,,7168444,qualitative,,6089332,,,In Vitro (Efficacy),,,,DNA levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.03, 0.1 or 0.3 increased cell adenosine triphosphate (ATP) levels up to 103, 118-132 or 118-155 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530317,,381034,21435216,MAIN,18526918,,,,,,,,,7168444,qualitative,,6089332,,,In Vitro (Efficacy),,,,DNA levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.03, 0.1 or 0.3 increased cell adenosine triphosphate (ATP) levels up to 109, 106-152 or 123-165 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530318,,381034,21435215,MAIN,18526917,,,,,,,,,7168444,qualitative,,6089332,,,In Vitro (Efficacy),,,,DNA levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.1 or 0.3 increased cell glutathione (GSH) levels up to 117 or 131 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530319,,381034,21435217,MAIN,18526919,,,,,,,,,7168445,qualitative,,6089333,,,In Vitro (Efficacy),,,,cell adenosine triphosphate (ATP) levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.03 or 0.1 increased cell adenosine triphosphate (ATP) levels up to 126 or 122 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530320,,381034,21435216,MAIN,18526918,,,,,,,,,7168445,qualitative,,6089333,,,In Vitro (Efficacy),,,,cell adenosine triphosphate (ATP) levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.03, 0.1 or 0.3 increased cell adenosine triphosphate (ATP) levels up to 126, 122-186 or 111-186 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530321,,381034,21435214,MAIN,33586252,,,,,,,,,7168445,qualitative,,6089333,,,In Vitro (Efficacy),,,,cell adenosine triphosphate (ATP) levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.03, 0.1 or 0.3 increased cell adenosine triphosphate (ATP) levels up to 90-101, 113-136 or 125-173 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530322,,381034,21435215,MAIN,18526917,,,,,,,,,7168445,qualitative,,6089333,,,In Vitro (Efficacy),,,,cell adenosine triphosphate (ATP) levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.1 or 0.3 increased cell adenosine triphosphate (ATP) levels up to 103 or 154 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530323,,381034,21435217,MAIN,18526919,,,,,,,,,7168446,qualitative,,6089338,,,In Vitro (Efficacy),,,,cell glutathione (GSH) levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.03 or 0.1 increased cell adenosine triphosphate (ATP) levels up to 129 or 128 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530324,,381034,21435214,MAIN,33586252,,,,,,,,,7168446,qualitative,,6089338,,,In Vitro (Efficacy),,,,cell glutathione (GSH) levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.03, 0.1 or 0.3 increased cell adenosine triphosphate (ATP) levels up to 109-147, 111-172 or 145-193 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530325,,381034,21435216,MAIN,18526918,,,,,,,,,7168446,qualitative,,6089338,,,In Vitro (Efficacy),,,,cell glutathione (GSH) levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.03, 0.1 or 0.3 increased cell adenosine triphosphate (ATP) levels up to 123, 117-151 or 114-202 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530326,,381034,21435215,MAIN,18526917,,,,,,,,,7168446,qualitative,,6089338,,,In Vitro (Efficacy),,,,cell glutathione (GSH) levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.1 or 0.3 increased cell glutathione (GSH) levels up to 122 or 147 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530327,,381034,21435214,MAIN,33586252,,,,,,,,,7168447,qualitative,,6089334,,,In Vitro (Efficacy),,,,cell protein levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.03 or 0.1 increased cell protein levels up to 115 or 121-148 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530328,,381034,21435216,MAIN,18526918,,,,,,,,,7168447,qualitative,,6089334,,,In Vitro (Efficacy),,,,cell protein levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,"title compound at 0.1 or 0.3 increased cell protein levels up to 129 or 131 from 100 in control group, respectively",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530329,,381034,21435215,MAIN,18526917,,,,,,,,,7168447,qualitative,,6089334,,,In Vitro (Efficacy),,,,cell protein levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,title compound at 0.1 increased cell protein levels up to 120 from 100 in control group,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530330,,381034,21435217,MAIN,18526919,,,,,,,,,7168447,qualitative,,6089334,,,In Vitro (Efficacy),,,,cell protein levels; increase in,,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,title compound at 0.1 increased cell protein levels up to 123 from 100 in control group,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530331,,381034,21435216,MAIN,18526918,,,,,,,,,7168448,qualitative,,6089337,,,In Vitro (Efficacy),,,,melanin synthesis; inhibition of,,,,,,,,,,,,,,,,,,,,,"title compound at 0.03 or 0.1 inhibted melanin synthesis (86 or 61 versus 100 in control, respectively)",ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530332,,381034,21435216,MAIN,18526918,,,,,,,,,7168449,qualitative,,6089339,,Cell/tumor cell: proliferation/viability/growth,Toxicity/Safety Pharmacology,,,,cytotoxic,Cytotoxic,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530333,,381034,21435217,MAIN,18526919,,,,,,,,,7168449,qualitative,,6089339,,Cell/tumor cell: proliferation/viability/growth,Toxicity/Safety Pharmacology,,,,cytotoxic,Cytotoxic,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530334,,381034,21435214,MAIN,33586252,,,,,,,,,7168449,qualitative,,6089339,,Cell/tumor cell: proliferation/viability/growth,Toxicity/Safety Pharmacology,,,,cytotoxic,Cytotoxic,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530335,,381034,21435215,MAIN,18526917,,,,,,,,,7168449,qualitative,,6089339,,Cell/tumor cell: proliferation/viability/growth,Toxicity/Safety Pharmacology,,,,cytotoxic,Cytotoxic,1806782,fibroblast,,,,human,,,,,,,,,,,human,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530336,,375487,21435227,MAIN,6854419,1675384,oral administration,,,,,,,7168450,qualitative,,6089414,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : pharmacokinetics  ,,1806790,,,,,rat,,,,,,,,,,,rat,,,"pharmacokinetic parameters of title compound administered as granule composition: AUC7h = 11.3 μg h/ml, Tmax = 1 h, Cmax = 3.7 μg/ml; harmacokinetic parameters of title compound administered as Zinnat(R) dryed syrup: AUC7h = 7.3 μg h/ml, Tmax",,,,,,,,,,2018/11/16,,,2018/11/22,
52530337,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168465,qualitative,,6089354,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : LPS-induced cerebral cortex IL-1β expression; inhibition of,,1806789,,,,,rat,,,,,,,,,,,rat,,,title compound (100 mg/kg) significantly decreased LPS-induced expression of IL-1β in cerebral cortex; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530338,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168479,qualitative,,6089368,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : LPS-induced cerebral cortex TNF-α expression; inhibition of,,1806789,,,,,rat,,,,,,,,,,,rat,,,title compound (100 mg/kg) significantly decreased LPS-induced expression of TNF-α in cerebral cortex; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530339,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168453,qualitative,,6089342,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   LPS-induced increase of iNOS expression; inhibition of,,1806789,,,,,rat,,,,,,,,,,,rat,,,title compound (100 mg/kg) significantly inhibited LPS-induced expression of iNOS in peritoneal macrophages; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530340,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168470,qualitative,,6089359,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : LPS-induced increase of serum IFN-γ level; inhibition of,,1806789,,,,,rat,,,,,,,,,,,rat,,,title compound (100 mg/kg) abolished LPS-mediated increase of IFN-γ level in serum; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530341,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168466,qualitative,,6089355,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : LPS-induced increase of serum IL-1β level; inhibition of,,1806789,,,,,rat,,,,,,,,,,,rat,,,title compound (100 mg/kg) abolished LPS-mediated increase of IL-1β level in serum; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530342,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168468,qualitative,,6089357,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : LPS-induced spleen IFN-γ expression; inhibition of,,1806789,,,,,rat,,,,,,,,,,,rat,,,title compound (100 mg/kg) significantly decreased LPS-induced expression of IFN-γ mRNA in spleen; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530343,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168458,qualitative,,6089347,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : LPS-induced spleen IL-1β expression; inhibition of,,1806789,,,,,rat,,,,,,,,,,,rat,,,title compound (100 mg/kg) significantly decreased LPS-induced expression of IL-1β mRNA in spleen; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530344,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168454,qualitative,,6089343,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : LPS-induced increase of serum TNF-α level; effect on,,1806789,,,,,rat,,,,,,,,,,,rat,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,,,2019/06/17,
52530345,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168463,qualitative,,6089352,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : LPS-induced spleen TNF-α expression; effect on,,1806789,,,,,rat,,,,,,,,,,,rat,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,,,2019/06/17,
52530346,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168461,qualitative,,6089350,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   spinal cord injury-induced impairment; effect on,,,,,,,,,,,,,,,,,,,,,"title compound (20 mg/kg) showed beneficial effect in the rat model of SCI, protected against apoptosis neurons and other cells, inhibited SCI-induced white matter vacuolization, tissue necrosis and demyelinization; diagram given",,,,,,,,,,2018/11/16,,,2018/11/22,
52530347,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168459,qualitative,,6089348,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   spinal cord iNOS expression; inhibition of,,,,,,,,3844661,,"Nitric oxide synthase, inducible",,Wild,"Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible",Target,Non Transfected,,,,title compound (20 mg/kg) markedly suppressed increase of iNOS mRNA and protein levels in spinal cord induced by SCI; diagram given,,,,,,,,,,2018/11/16,"Nitric oxide synthase, inducible",,2018/11/22,
52530348,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168460,qualitative,,6089349,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   spinal cord glial fibrillary acidic protein (GFAP) level; effect on,,,,,,,,3844670,,Glial fibrillary acidic protein,,Wild,Glial fibrillary acidic protein:Wild,Glial fibrillary acidic protein:Wild,Glial fibrillary acidic protein,Target,Non Transfected,,,,title compound (20 mg/kg) markedly suppressed increase of GFAP level in spinal cord induced by SCI; diagram given,,,,,,,,,,2018/11/16,Glial fibrillary acidic protein,,2018/11/22,
52530349,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168476,qualitative,,6089365,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : spleen TNF-α expression; effect on,,1806789,,,,,rat,3844672,,Tumor necrosis factor,,Wild,Tumor necrosis factor:Wild,Tumor necrosis factor:Wild,Tumor necrosis factor,Target,Non Transfected,rat,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,Tumor necrosis factor,,2019/06/17,
52530350,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168477,qualitative,,6089366,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : spleen IL-1β expression; effect on,,1806789,,,,,rat,3844677,,Interleukin-1 beta,,Wild,Interleukin-1 beta:Wild,Interleukin-1 beta:Wild,Interleukin-1 beta,Target,Non Transfected,rat,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,Interleukin-1 beta,,2019/06/17,
52530351,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168455,qualitative,,6089344,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : spleen IFNγ expression; effect on,,1806789,,,,,rat,3844682,,Interferon gamma,,Wild,Interferon gamma:Wild,Interferon gamma:Wild,Interferon gamma,Target,Non Transfected,rat,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,Interferon gamma,,2019/06/17,
52530352,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168478,qualitative,,6089367,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   active EAE; treatment of,,,,,,,,,,,,,,,,,,,,,mice treated with title compound (5 mg/kg) developed significantly less severe disease; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530353,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168469,qualitative,,6089358,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   passive EAE; treatment of,,,,,,,,,,,,,,,,,,,,,mice treated with title compound (5 mg/kg) developed significantly less severe disease; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530354,,374967,21435224,MAIN,4720754,161639,oral administration,,,Marketed,,,,7168457,qualitative,,6089346,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : kinic acid (KA)-induced IL-1β expression; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 mg/kg) inhibited expression of IL-1β in hippocampus induced by KA; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530355,,374967,21435229,MAIN,8373630,1808788,oral administration,,,,,,,7168457,qualitative,,6089346,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : kinic acid (KA)-induced IL-1β expression; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 mg/kg) inhibited expression of IL-1β in hippocampus induced by KA; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530356,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168475,qualitative,,6089364,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   kinic acid (KA)-induced iNOS expression; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 mg/kg) inhibited expression of iNOS in hippocampus induced by KA; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530357,,374967,21435229,MAIN,8373630,1808788,oral administration,,,,,,,7168475,qualitative,,6089364,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   kinic acid (KA)-induced iNOS expression; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 mg/kg) inhibited expression of iNOS in hippocampus induced by KA; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530358,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168464,qualitative,,6089353,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   kinic acid (KA)-induced neuronal cell death; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 mg/kg) inhibited neuronal cell death induced by KA in hippocampus; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530359,,374967,21435229,MAIN,8373630,1808788,oral administration,,,,,,,7168464,qualitative,,6089353,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   kinic acid (KA)-induced neuronal cell death; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 mg/kg) inhibited neuronal cell death induced by KA in hippocampus; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530360,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168456,qualitative,,6089345,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   kinic acid (KA)-induced seizure; prevention of,,,,,,,,,,,,,,,,,,,,,title compound (10 mg/kg) significantly attenuated seizures induced by KA; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530361,,374967,21435229,MAIN,8373630,1808788,oral administration,,,,,,,7168456,qualitative,,6089345,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   kinic acid (KA)-induced seizure; prevention of,,,,,,,,,,,,,,,,,,,,,title compound (10 mg/kg) significantly attenuated seizures induced by KA; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530362,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168451,qualitative,,6089340,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : kinic acid (KA)-induced TNF-α expression; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 mg/kg) inhibited expression of TNF-α in hippocampus induced by KA; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530363,,374967,21435229,MAIN,8373630,1808788,oral administration,,,,,,,7168451,qualitative,,6089340,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : kinic acid (KA)-induced TNF-α expression; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 mg/kg) inhibited expression of TNF-α in hippocampus induced by KA; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530364,,374967,21435219,MAIN,18337537,2500090,intravenous administration,,,,,,,7168467,qualitative,,6089356,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   brain cell apoptosis; inhibition of,,,,,,,,,,,,,,,,,,,,,administration of title compound (1mg/kg) after onset of MCAO (20 min) inhibited apoptosis of brain cells induced by brain ischemia; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530365,,374967,21435219,MAIN,18337537,2500090,intravenous administration,,,,,,,7168473,qualitative,,6089362,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   brain ischemia; effect on,,,,,,,,,,,,,,,,,,,,,"administration of title compound (1mg/kg) after onset of MCAO (20 min) reduced the infarction, infarct volume and improved neurological evaluation score (1.1 compared 2.7 before administration) and all animals received title compound were survived up",,,,,,,,,,2018/11/16,,,2018/11/22,
52530366,,374967,21435219,MAIN,18337537,2500090,intravenous administration,,,,,,,7168462,qualitative,,6089351,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   brain iNOS expression; inhibition of,,,,,,,,3844662,,"Nitric oxide synthase, inducible",,Wild,"Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible",Target,Non Transfected,,,,administration of title compound (1mg/kg) after onset of MCAO (20 min) significantly reduced expression of iNOS in brain compared to untreated group; diagram given,,,,,,,,,,2018/11/16,"Nitric oxide synthase, inducible",,2018/11/22,
52530367,,374967,21435219,MAIN,18337537,2500090,intravenous administration,,,,,,,7168452,qualitative,,6089341,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   brain caspase-3 activity; inhibition of,,,,,,,,3844660,,Caspase-3,,Wild,Caspase-3:Wild,Caspase-3:Wild,Caspase-3,Target,Non Transfected,,,,administration of title compound (1mg/kg) after onset of MCAO (20 min) returned caspase-3 activity increased by brain ischemia to basal level; diagram given,,,,,,,,,,2018/11/16,Caspase-3,,2018/11/22,
52530368,,374967,21435219,MAIN,18337537,2500090,intravenous administration,,,,,,,7168474,qualitative,,6089363,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : brain TNF-α expression; inhibition of,,,,,,,,3844671,,Tumor necrosis factor,,Wild,Tumor necrosis factor:Wild,Tumor necrosis factor:Wild,Tumor necrosis factor,Target,Non Transfected,,,,administration of title compound (1mg/kg) after onset of MCAO (20 min) significantly reduced expression of TNF-α in brain compared to untreated group; diagram given,,,,,,,,,,2018/11/16,Tumor necrosis factor,,2018/11/22,
52530369,,374967,21435219,MAIN,18337537,2500090,intravenous administration,,,,,,,7168472,qualitative,,6089361,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect : brain IL-1β expression; inhibition of,,,,,,,,3844676,,Interleukin-1 beta,,Wild,Interleukin-1 beta:Wild,Interleukin-1 beta:Wild,Interleukin-1 beta,Target,Non Transfected,,,,administration of title compound (1mg/kg) after onset of MCAO (20 min) significantly reduced expression of IL-1β in brain compared to untreated group; diagram given,,,,,,,,,,2018/11/16,Interleukin-1 beta,,2018/11/22,
52530370,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168471,qualitative,,6089360,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,"Bioassay :  Efficacy of D-PDMP in controlling NOS induction in spinal cord injury (SCI). To test the physiological relevance of previous observations and further investigate the role of LacCer in the induction of NOS in neuro-inflammatory disease, the effect of D-PDMP in the rat spinal cord injury model was examined.",Toxic : Acute,1806789,,,,,rat,,,,,,,,,,,rat,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,,,2019/06/17,
52530371,,374967,21435223,MAIN,4720754,161639,,,,Marketed,,,,7168482,qualitative,,6089371,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : anti-CD3/CD28-mediated increase of IFN-γ production; effect on,,,,,,,,,,,,,,,,,,,,,title compound (10 - 20 μmol/l) attenuated anti-CD3/CD28-mediated increase of IFN-γ production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530372,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168514,qualitative,,6089403,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   anti-CD3/CD28-mediated increase of IL-10 production; effect on,,,,,,,,,,,,,,,,,,,,,title compound (10 - 20 μmol/l) enhanced anti-CD3/CD28-mediated increase of IL-10 production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530373,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168508,qualitative,,6089397,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   anti-CD3/CD28-mediated increase of IL-4 production; effect on,,,,,,,,,,,,,,,,,,,,,title compound (10 - 20 μmol/l) enhanced anti-CD3/CD28-mediated increase of IL-4 production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530374,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168506,qualitative,,6089395,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   anti-CD3/CD28-mediated increase of IL-5 production; effect on,,,,,,,,,,,,,,,,,,,,,title compound (10 - 20 μmol/l) enhanced anti-CD3/CD28-mediated increase of IL-5 production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530375,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168487,qualitative,,6089376,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : anti-CD3/CD28-mediated increase of TNF-α production; effect on,,,,,,,,,,,,,,,,,,,,,title compound (10 - 20 μmol/l) attenuated anti-CD3/CD28-mediated increase of TNF-α production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530376,,374967,21435218,MAIN,18337537,2500090,,,,,,,,7168510,qualitative,,6089399,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS/IFNγ-increased iNOS expression; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (0.1 - 2 mmol/l) dose-dependently inhibited expression of iNOS increased by mixture of LPS and IFNγ; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530377,,374967,21435226,MAIN,8096650,1781727,,,,,,,,7168511,qualitative,,6089400,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS/IFN-γ-increased iNOS expression; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 - 50 μmol/l) dose-dependently decreased iNOS mRNA and protein levels increased by mixture of LPS and IFN-γ; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530378,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168493,qualitative,,6089382,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS/IFN-γ-stimulated nitric oxide production; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 - 50 μmol/l) dose-dependently inhibited production of nitric oxide stimulated with mixture of LPS and IFN-γ; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530379,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168485,qualitative,,6089374,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-induced nitric oxide production; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 μmol/l) decreased NO production in astrocytes to 5.2 from 25.3 nmol/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,,,2018/11/22,
52530380,,374967,21435222,MAIN,3917627,1486056,,,,Discontinued (Phase II),,,,7168485,qualitative,,6089374,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-induced nitric oxide production; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (5 mmol/l) decreased NO production in astrocytes to 5.4 from 25.3 nmol/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,,,2018/11/22,
52530381,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168517,qualitative,,6089406,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-induced nitric oxide production; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 μmol/l) decreased NO production in astrocytes to 7.2 from 118.5 nmol/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,,,2018/11/22,
52530382,,374967,21435222,MAIN,3917627,1486056,,,,Discontinued (Phase II),,,,7168517,qualitative,,6089406,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-induced nitric oxide production; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (5 mmol/l) decreased NO production in astrocytes to 9.5 from 118.5 nmol/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,,,2018/11/22,
52530383,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168497,qualitative,,6089386,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-induced nitric oxide production; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (10 μmol/l) decreased NO production in astrocytes to 5.9 from 81.2 nmol/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,,,2018/11/22,
52530384,,374967,21435222,MAIN,3917627,1486056,,,,Discontinued (Phase II),,,,7168497,qualitative,,6089386,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-induced nitric oxide production; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound (5 mmol/l) decreased NO production in astrocytes to 6.9 from 81.2 nmol/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,,,2018/11/22,
52530385,,374967,21435220,MAIN,38255,437880,,,,Preclinical,,,,7168502,qualitative,,6089391,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-stimulated nitric oxide production; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited LPS-stimulated nitric oxide production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530386,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168505,qualitative,,6089394,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-stimulated nitric oxide production; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited LPS-stimulated nitric oxide production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530387,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168515,qualitative,,6089404,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-stimulated nitric oxide production; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited LPS-stimulated nitric oxide production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530388,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168480,qualitative,,6089369,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : PLP-mediated increase of IFN-γ production; effect on,,,,,,,,,,,,,,,,,,,,,title compound (10 - 20 μmol/l) attenuated PLP-mediated increase of IFN-γ production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530389,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168507,qualitative,,6089396,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   PLP-mediated increase of IL-10 production; effect on,,,,,,,,,,,,,,,,,,,,,title compound (10 - 20 μmol/l) enhanced PLP-mediated increase of IL-10 production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530390,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168499,qualitative,,6089388,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   PLP-mediated increase of IL-4 production; effect on,,,,,,,,,,,,,,,,,,,,,title compound (10 - 20 μmol/l) enhanced PLP-mediated increase of IL-4 production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530391,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168496,qualitative,,6089385,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   PLP-mediated increase of IL-5 production; effect on,,,,,,,,,,,,,,,,,,,,,title compound (10 - 20 μmol/l) enhanced PLP-mediated increase of IL-5 production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530392,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168491,qualitative,,6089380,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : PLP-mediated increase of TNF-α production; effect on,,,,,,,,,,,,,,,,,,,,,title compound (10 - 20 μmol/l) attenuated PLP-mediated increase of TNF-α production; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530393,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168503,qualitative,,6089392,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   nitric oxide production; effect on,,,,,,,,,,,,,,,,,,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,,,2019/06/17,
52530394,,374967,21435219,MAIN,18337537,2500090,intravenous administration,,,,,,,7168494,qualitative,,6089383,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   iNOS expression; effect on,,,,,,,,3844665,,"Nitric oxide synthase, inducible",,Wild,"Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible",Target,Non Transfected,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,"Nitric oxide synthase, inducible",,2019/06/17,
52530395,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168501,qualitative,,6089390,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   iNOS expression; effect on,,,,,,,,3844667,,"Nitric oxide synthase, inducible",,Wild,"Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible",Target,Non Transfected,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,"Nitric oxide synthase, inducible",,2019/06/17,
52530396,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168489,qualitative,,6089378,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-induced IL-6 production; inhibition of,,,,,,,,3844681,,Interleukin-6,,Wild,Interleukin-6:Wild,Interleukin-6:Wild,Interleukin-6,Target,Non Transfected,,,,title compound (10 μmol/l) decreased IL-6 production in astrocytes to 0.8 from 136.5 ng/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,Interleukin-6,,2018/11/22,
52530397,,374967,21435222,MAIN,3917627,1486056,,,,Discontinued (Phase II),,,,7168489,qualitative,,6089378,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-induced IL-6 production; inhibition of,,,,,,,,3844681,,Interleukin-6,,Wild,Interleukin-6:Wild,Interleukin-6:Wild,Interleukin-6,Target,Non Transfected,,,,title compound (5 mmol/l) decreased IL-6 production in astrocytes to 10.2 from 350.0 ng/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,Interleukin-6,,2018/11/22,
52530398,,374967,21435219,MAIN,18337537,2500090,intravenous administration,,,,,,,7168481,qualitative,,6089370,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-increased iNOS expression; inhibition of,,1806787,BV-2 cell line,,,,rat,3844663,,"Nitric oxide synthase, inducible",,Wild,"Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible",Target,Non Transfected,rat,,,title compound (0.1 - 2 mmol/l) dose-dependently inhibited expression of iNOS increased by LPS; diagram given,,,,,,,,,,2018/11/16,"Nitric oxide synthase, inducible",,2018/11/22,
52530399,,374967,21435219,MAIN,18337537,2500090,intravenous administration,,,,,,,7168495,qualitative,,6089384,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   iNOS expression; effect on,,1806787,BV-2 cell line,,,,rat,3844666,,"Nitric oxide synthase, inducible",,Wild,"Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible",Target,Non Transfected,rat,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,"Nitric oxide synthase, inducible",,2019/06/17,
52530400,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168486,qualitative,,6089375,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS-induced TNF-α expression; inhibition of,,,,,,,,3844673,,Tumor necrosis factor,,Wild,Tumor necrosis factor:Wild,Tumor necrosis factor:Wild,Tumor necrosis factor,Target,Non Transfected,,,,title compound inhibited LPS-induced expression of TNF-α and TNFα mRNA in a dose-dependent manner; diagram given,,,,,,,,,,2018/11/16,Tumor necrosis factor,,2018/11/22,
52530401,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168516,qualitative,,6089405,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS-induced TNF-α production; inhibition of,,,,,,,,3844675,,Tumor necrosis factor,,Wild,Tumor necrosis factor:Wild,Tumor necrosis factor:Wild,Tumor necrosis factor,Target,Non Transfected,,,,title compound (10 μmol/l) decreased TNF-α production in astrocytes to 0.3 from 5.3 ng/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,Tumor necrosis factor,,2018/11/22,
52530402,,374967,21435222,MAIN,3917627,1486056,,,,Discontinued (Phase II),,,,7168516,qualitative,,6089405,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS-induced TNF-α production; inhibition of,,,,,,,,3844675,,Tumor necrosis factor,,Wild,Tumor necrosis factor:Wild,Tumor necrosis factor:Wild,Tumor necrosis factor,Target,Non Transfected,,,,title compound (10 μmol/l) decreased TNF-α production in astrocytes to 0.4 from 5.3 ng/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,Tumor necrosis factor,,2018/11/22,
52530403,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168512,qualitative,,6089401,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : TNF-α expression; effect on,,,,,,,,3844674,,Tumor necrosis factor,,Wild,Tumor necrosis factor:Wild,Tumor necrosis factor:Wild,Tumor necrosis factor,Target,Non Transfected,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,Tumor necrosis factor,,2019/06/17,
52530404,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168498,qualitative,,6089387,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS/IFN-γ-increased iNOS expression; inhibition of,,1806788,C6,,,,rat,,,,,,,,,,,rat,,,title compound (10 - 50 μmol/l) dose-dependently decreased iNOS mRNA and protein levels increased by mixture of LPS and IFN-γ; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530405,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168488,qualitative,,6089377,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS/IFN-γ-stimulated nitric oxide production; inhibition of,,1806788,C6,,,,rat,,,,,,,,,,,rat,,,title compound (10 - 50 μmol/l) dose-dependently inhibited production of nitric oxide stimulated with mixture of LPS and IFN-γ; diagram given,,,,,,,,,,2018/11/16,,,2018/11/22,
52530406,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168490,qualitative,,6089379,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   nitric oxide production; effect on,,1806788,C6,,,,rat,,,,,,,,,,,rat,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,,,2019/06/17,
52530407,,374967,21435228,MAIN,8096650,1781727,intraperitoneal administration,,,,,,,7168484,qualitative,,6089373,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   iNOS expression; effect on,,1806788,C6,,,,rat,3844664,,"Nitric oxide synthase, inducible",,Wild,"Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible:Wild","Nitric oxide synthase, inducible",Target,Non Transfected,rat,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,"Nitric oxide synthase, inducible",,2019/06/17,
52530408,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168509,qualitative,,6089398,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   LPS-induced IL-6 expression; inhibition of,,,,,,,,3844668,,Glucagon,,Wild,Glucagon:Wild,Glucagon:Wild,Glucagon,Target,Non Transfected,,,,title compound inhibited LPS-induced expression of IL-6 and IL-6 mRNA in a dose-dependent manner; diagram given,,,,,,,,,,2018/11/16,Glucagon,,2018/11/22,
52530409,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168518,qualitative,,6089407,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   IL-6 expression; effect on,,,,,,,,3844669,,Glucagon,,Wild,Glucagon:Wild,Glucagon:Wild,Glucagon,Target,Non Transfected,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,Glucagon,,2019/06/17,
52530410,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168519,qualitative,,6089408,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS-induced IL-1β expression; inhibition of,,,,,,,,3844680,,Interleukin-1 beta,,Wild,Interleukin-1 beta:Wild,Interleukin-1 beta:Wild,Interleukin-1 beta,Target,Non Transfected,,,,title compound inhibited LPS-induced expression of IL-1β and IL-1β mRNA in a dose-dependent manner; diagram given,,,,,,,,,,2018/11/16,Interleukin-1 beta,,2018/11/22,
52530411,,374967,21435225,MAIN,4720754,161639,intraperitoneal administration,,,Marketed,,,,7168492,qualitative,,6089381,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS-induced IL-1β production; inhibition of,,,,,,,,3844678,,Interleukin-1 beta,,Wild,Interleukin-1 beta:Wild,Interleukin-1 beta:Wild,Interleukin-1 beta,Target,Non Transfected,,,,title compound (10 μmol/l) decreased IL-1β production in astrocytes to 0.8 from 10.4 ng/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,Interleukin-1 beta,,2018/11/22,
52530412,,374967,21435222,MAIN,3917627,1486056,,,,Discontinued (Phase II),,,,7168492,qualitative,,6089381,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : LPS-induced IL-1β production; inhibition of,,,,,,,,3844678,,Interleukin-1 beta,,Wild,Interleukin-1 beta:Wild,Interleukin-1 beta:Wild,Interleukin-1 beta,Target,Non Transfected,,,,title compound (5 mmol/l) decreased IL-1β production in astrocytes to 2.4 from 28.2 ng/24 h/mg protein in LPS treated cells,,,,,,,,,,2018/11/16,Interleukin-1 beta,,2018/11/22,
52530413,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168504,qualitative,,6089393,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : IL-1β expression; effect on,,,,,,,,3844679,,Interleukin-1 beta,,Wild,Interleukin-1 beta:Wild,Interleukin-1 beta:Wild,Interleukin-1 beta,Target,Non Transfected,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,Interleukin-1 beta,,2019/06/17,
52530414,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168513,qualitative,,6089402,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : microglia cells of Sprague-Dawley rat,Cytotoxic,,,,,,,,,,,,,,,,,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,,,2019/06/17,
52530415,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168500,qualitative,,6089389,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : peritoneal macrophages of Sprague-Dawley rat,Cytotoxic,,,,,,,,,,,,,,,,,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,,,2019/06/17,
52530416,,374967,21435221,MAIN,38255,437880,intraperitoneal administration,,,Preclinical,,,,7168483,qualitative,,6089372,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : primary astrocytes of Sprague-Dawley rat,Cytotoxic,,,,,,,,,,,,,,,,,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,,,2019/06/17,
52530417,,374967,21435235,MAIN,18337536,,,,,,,,,7168520,qualitative,,6089409,,,In Vitro (Efficacy),,,,D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (D-PDMP)-mediated decrease of iNOS expression; effect on,,,,,,,,,,,,,,,,,,,,,title substance (5 - 10 μmol/l) attenuated D-PDMP-mediated decrease of iNOS mRNA and protein levels; diagram given,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530418,,374967,21435234,MAIN,18337535,,,,,,,,,7168520,qualitative,,6089409,,,In Vitro (Efficacy),,,,D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (D-PDMP)-mediated decrease of iNOS expression; effect on,,,,,,,,,,,,,,,,,,,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530419,,374967,21435235,MAIN,18337536,,,,,,,,,7168521,qualitative,,6089413,,,In Vitro (Efficacy),,,,D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (D-PDMP)-mediated decrease of iNOS expression; effect on,,,,,,,,,,,,,,,,,,,,,title substance (5 - 10 μmol/l) attenuated D-PDMP-mediated decrease of iNOS mRNA and protein levels; diagram given,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530420,,374967,21435234,MAIN,18337535,,,,,,,,,7168522,qualitative,,6089412,,,In Vitro (Efficacy),,,,D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (D-PDMP)-mediated inhibition of NO production; effect on,,,,,,,,,,,,,,,,,,,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530421,,374967,21435235,MAIN,18337536,,,,,,,,,7168523,qualitative,,6089410,,,In Vitro (Efficacy),,,,D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (D-PDMP)-mediated inhibition of nitric oxide production; effect on,,,,,,,,,,,,,,,,,,,,,title substance (5 - 10 μmol/l) attenuated D-PDMP-mediated inhibition of NO production; diagram given,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530422,,374967,21435234,MAIN,18337535,,,,,,,,,7168523,qualitative,,6089410,,,In Vitro (Efficacy),,,,D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (D-PDMP)-mediated inhibition of nitric oxide production; effect on,,,,,,,,,,,,,,,,,,,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530423,,374967,21435235,MAIN,18337536,,,,,,,,,7168524,qualitative,,6089411,,,In Vitro (Efficacy),,,,D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (D-PDMP)-mediated inhibition of nitric oxide production; effect on,,,,,,,,,,,,,,,,,,,,,title substance (5 - 10 μmol/l) attenuated D-PDMP-mediated inhibition of nitric oxide production; diagram given,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530424,,374967,21435232,MAIN,18337533,,,,,,,,,7168524,qualitative,,6089411,,,In Vitro (Efficacy),,,,D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (D-PDMP)-mediated inhibition of nitric oxide production; effect on,,,,,,,,,,,,,,,,,,,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530425,,374967,21435231,MAIN,18337532,,,,,,,,,7168524,qualitative,,6089411,,,In Vitro (Efficacy),,,,D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (D-PDMP)-mediated inhibition of nitric oxide production; effect on,,,,,,,,,,,,,,,,,,,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530426,,374967,21435233,MAIN,18337534,,,,,,,,,7168524,qualitative,,6089411,,,In Vitro (Efficacy),,,,D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (D-PDMP)-mediated inhibition of nitric oxide production; effect on,,,,,,,,,,,,,,,,,,,,,,ND,,,,,,,,,2018/11/16,,,2018/11/22,
52530427,,380607,21435236,MAIN,1445814,161636,,,,,,,,7168530,qualitative,,6089419,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   biodistribution,,,,,,,,,,,,,,,,,,,,,transcatheter arterial embolisation using title compound-loaded microspheres in rabbit model of liver cancer (Vx-2); pharmacokinetic profiles of plasma levels of title compound from intraarterial title compound injection compared to title compound-loaded,,,,,,,,,,2018/11/16,,,2018/11/22,
52530428,,380607,21435236,MAIN,1445814,161636,,,,,,,,7168528,qualitative,,6089416,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   biodistribution,,,,,,,,,,,,,,,,,,,,,healthy porcine liver model; title compound-loaded embolisation microspheres were effective to deliver title compound to healthy liver tissue with large areas of necrosis surrounding vessels and even evident on outside of capsule of liver,,,,,,,,,,2018/11/16,,,2018/11/22,
52530429,,380607,21435236,MAIN,1445814,161636,,,,,,,,7168529,qualitative,,6089417,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : VX2 tumour cells injected into hindlegs of New Zealand White rabbit,antineoplastic agent,,,,,,,,,,,,,,,,,,,,"transcatheter arterial embolisation using title compound-loaded microspheres in rabbit model of liver cancer (Vx-2); histological evaluation; intraarterially injection of title compound resulted in 30% necrosis of tumour, in contrast, treatment of rabbits",,,,,,,,,,2018/11/16,,,2018/11/22,
52530430,,380607,21435236,MAIN,1445814,161636,,,,,,,,7168527,qualitative,,6089420,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : antitumor,antineoplastic agent,,,,,,,,,,,,,,,,,,,,"transcatheter arterial embolisation using title compound-loaded microspheres in rabbit model of liver cancer (Vx-2); histological evaluation; intraarterially injection of title compound resulted in 30% necrosis of tumour, in contrast, treatment of rabbits",,,,,,,,,,2018/11/16,,,2018/11/22,
52530431,,380607,21435236,MAIN,1445814,161636,,,,,,,,7168525,qualitative,,6089415,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : biodistribution  ,,1806791,,,,,pig,,,,,,,,,,,pig,,,healthy porcine liver model; title compound-loaded embolisation microspheres were effective to deliver title compound to healthy liver tissue with large areas of necrosis surrounding vessels and even evident on outside of capsule of liver,,,,,,,,,,2018/11/16,,,2018/11/22,
52530432,,380607,21435236,MAIN,1445814,161636,,,,,,,,7168526,qualitative,,6089418,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : biodistribution  ,,,,,,,,,,,,,,,,,,,,,transcatheter arterial embolisation using title compound-loaded microspheres in rabbit model of liver cancer (Vx-2); pharmacokinetic profiles of plasma levels of title compound from intraarterial title compound injection compared to title compound-loaded,,,,,,,,,,2018/11/16,,,2018/11/22,
52530433,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168531,qualitative,,6089421,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Effect :   chemosensitizing,,,,,,,,,,,,,,,,,,,,,"pulsatile administration of title compound had no significant anti-tumor activity, however, combination of sub-therapeutic melpahalan followed by sub-therapeutic title compound had synergistic effect in prolonging survival of mice",,,,,,,,,,2018/11/16,,,2018/11/22,
52530434,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168534,qualitative,,6089424,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Target : multiple myeloma MM-1 S-Luc cells intravenously injected into NOD/SCID mouse,antineoplastic agent,,,,,,,,,,,,,,,,,,,,"mouse xenograft model; title compound monotherapy (10 mg/kg, i. p. twice daily) significantly suppressed tumor growth and prolonged survival of mice",,,,,,,,,,2018/11/16,,,2018/11/22,
52530435,,379542,21435240,MAIN,18526473,2536074,oral administration,,,,,,,7168534,qualitative,,6089424,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Target : multiple myeloma MM-1 S-Luc cells intravenously injected into NOD/SCID mouse,antineoplastic agent,,,,,,,,,,,,,,,,,,,,"mouse xenograft model; title compound monotherapy (50 mg/kg, orally twice daily) significantly suppressed tumor growth and prolonged survival of mice",,,,,,,,,,2018/11/16,,,2018/11/22,
52530436,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168532,qualitative,,6089422,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Target : multiple myeloma MM-1 S-Luc cells intravenously injected into NOD/SCID mouse,antineoplastic agent,,,,,,,,,,,,,,,,,,,,orthotopic xenograft mouse model of multiple myeloma; title compound significantly reduced tumor burden after 15 days of treatment,,,,,,,,,,2018/11/16,,,2018/11/22,
52530437,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168533,qualitative,,6089423,In vivo Measurement,In vivo Measurement,In Vivo (Animal models),,,,Target : multiple myeloma MM-1 S-Luc cells intravenously injected into NOD/SCID mouse,Toxic,,,,,,,,,,,,,,,,,,,,"mouse xenograft model; title compound monotherapy (10 mg/kg, i. p. twice daily) did not show difference in body weight between treatment groups and no other significant treatment-related toxicity",,,,,,,,,,2018/11/16,,,2018/11/22,
52530438,,379542,21435237,MAIN,18526472,2536073,,,,,,,,7168604,qualitative,,6089494,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   chemosensitizing,,,,,,,,,,,,,,,,,,,,,"title compound synergistically sensitized primary MM cells to action of Dexamethasone, Doxorubicine and Melphalan, in addition, title compound sensitized primary MM cells to proteasome inhibitor bortezomib",,,,,,,,,,2018/11/16,,,2018/11/22,
52530439,,379542,21435239,MAIN,18526473,2536074,,,,,,,,7168597,qualitative,,6089487,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   chemosensitizing,,,,,,,,,,,,,,,,,,,,,title compound treatment enhanced in vitro anti-MM activities of doxorubicin in MM-1S cells,,,,,,,,,,2018/11/16,,,2018/11/22,
52530440,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168574,qualitative,,6089464,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : NFκB activity; inhibition of,,,,,,,,,,,,,,,,,,,,,title compound significantly impaired NFκB DNA binding activity in primary MM cells,,,,,,,,,,2018/11/16,,,2018/11/22,
52530441,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168571,qualitative,,6089461,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   protein expression; inhibition of,,,,,,,,,,,,,,,,,,,,,"title compound exposed samples showed marked reduction in level of phospho-IGF-IR and phospho-Akt, compared to vehicle treated controls",,,,,,,,,,2018/11/16,,,2018/11/22,
52530442,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168621,qualitative,,6089511,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect : HIF-1α activity; inhibition of,,,,,,,,3844685,,Hypoxia-inducible factor-1 alpha,,Wild,Hypoxia-inducible factor-1 alpha:Wild,Hypoxia-inducible factor-1 alpha:Wild,Hypoxia-inducible factor-1 alpha,Target,Non Transfected,,,,title compound inhibited HIF-1α DNA binding activity in primary multiple myeloma cells,,,,,,,,,,2018/11/16,Hypoxia-inducible factor-1 alpha,,2018/11/22,
52530443,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168553,qualitative,,6089443,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   VEGF production; inhibition of,,,,,,,,3844684,,Vascular endothelial growth factor A,,Wild,Vascular endothelial growth factor A:Wild,Vascular endothelial growth factor A:Wild,Vascular endothelial growth factor A,Target,Non Transfected,,,,title compound treatment decreased production of VEGF by bone marrow stromal cells,,,,,,,,,,2018/11/16,Vascular endothelial growth factor A,,2018/11/22,
52530444,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168607,qualitative,,6089497,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : breast cancer MDA-MB231- LucNeo cells inoculated in human bone chips implanted into nude mouse,antineoplastic agent,,,,,,,,,,,,,,,,,,,,title compound demonstrated clear anti-tumor effect in mouse model of breast cancer metastases to bone,,,,,,,,,,2018/11/16,,,2018/11/22,
52530445,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168579,qualitative,,6089469,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : glioma U87-LucNeo cells stereotactically implanted into brains of nude mouse,antineoplastic agent,,,,,,,,,,,,,,,,,,,,title compound showed additive antitumor efficacy in combination with AMD3100 (CXCR4 inhibitor),,,,,,,,,,2018/11/16,,,2018/11/22,
52530446,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168557,qualitative,,6089457,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806806,786-O cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530447,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168573,qualitative,,6089463,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : acute erythroleukemia KG-1a cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530448,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168603,qualitative,,6089493,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : acute lymphocytic leukemia REH cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530449,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168581,qualitative,,6089471,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : acute myelomonoblastic leukemia GDM-1 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530450,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168578,qualitative,,6089468,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : diffuse large B-cell lymphomas DHL-10 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530451,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168614,qualitative,,6089504,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : diffuse large B-cell lymphomas DHL-4 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530452,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168615,qualitative,,6089505,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : diffuse large B-cell lymphomas DHL-7 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530453,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168551,qualitative,,6089441,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : diffuse large B-cell lymphomas DHL-8 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530454,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168592,qualitative,,6089482,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma ARD cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530455,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168540,qualitative,,6089430,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma ARD cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530456,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168618,qualitative,,6089508,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma ARK cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530457,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168596,qualitative,,6089486,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma ARK cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530458,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168602,qualitative,,6089492,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma Brown cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530459,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168611,qualitative,,6089501,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma Dox40 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530460,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168612,qualitative,,6089502,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma Dox40 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530461,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168590,qualitative,,6089480,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma EJM cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530462,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168549,qualitative,,6089439,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma EJM cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530463,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168587,qualitative,,6089477,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma INA-6 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530464,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168584,qualitative,,6089474,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma INA-6 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530465,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168545,qualitative,,6089435,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma KMS-12-BM cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530466,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168555,qualitative,,6089445,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma KMS-12-BM cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530467,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168548,qualitative,,6089438,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma LP-1 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530468,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168608,qualitative,,6089498,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma LP-1 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530469,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168577,qualitative,,6089467,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma LR5 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530470,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168622,qualitative,,6089512,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma LR5 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530471,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168601,qualitative,,6089491,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma MM-1R cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound significantly suppressed serum-stimulated increase of total population of viable tumor cells in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530472,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168610,qualitative,,6089500,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma MM-1R cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530473,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168580,qualitative,,6089470,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma MM-1S cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound significantly suppressed serum-stimulated increase of total population of viable tumor cells in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530474,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168539,qualitative,,6089429,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma MM-1S-Akt cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530475,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168535,qualitative,,6089425,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma MM-1S-Bcl-2 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530476,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168617,qualitative,,6089507,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma MM-1S-TR-15 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530477,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168537,qualitative,,6089427,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma MR20 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530478,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168541,qualitative,,6089431,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma MR20 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530479,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168550,qualitative,,6089440,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma M-1S cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound at 0.5 μM significantly inhibited basal survival of primary MM cells,,,,,,,,,,2018/11/16,,,2018/11/22,
52530480,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168588,qualitative,,6089478,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma M-1S cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,"title compound at 0.5 μM showed in vitro activity against primary MM tumor cells isolated from patient resistant to cytotoxic chemotherapy, thalidomide, CC-5013, and PS-341, title compound supressed serum-stimulated survival of primary MM tumor cells;",,,,,,,,,,2018/11/16,,,2018/11/22,
52530481,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168613,qualitative,,6089503,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma M-1S cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530482,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168542,qualitative,,6089432,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma M-1S-Bcl-2 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530483,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168546,qualitative,,6089436,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma M-1S-TR-15 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530484,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168552,qualitative,,6089442,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma OCI-My5 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530485,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168536,qualitative,,6089426,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma OCI-My7 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530486,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168606,qualitative,,6089496,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma OCl-My5 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530487,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168609,qualitative,,6089499,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma OCl-My7 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530488,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168586,qualitative,,6089476,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma OPM-1 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530489,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168538,qualitative,,6089428,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma OPM-1 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530490,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168616,qualitative,,6089506,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma RPMI-8226/S cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound significantly suppressed serum-stimulated increase of total population of viable tumor cells in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530491,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168620,qualitative,,6089510,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma RPMI-8226/S cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530492,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168575,qualitative,,6089465,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma XG-1 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530493,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168544,qualitative,,6089434,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : multiple myeloma XG-1 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530494,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168583,qualitative,,6089473,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : retinoblastoma WERI cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530495,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168595,qualitative,,6089485,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : RL cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530496,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168598,qualitative,,6089488,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : sarcomas TC108 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530497,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168594,qualitative,,6089484,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : sarcomas TC248 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530498,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168576,qualitative,,6089466,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : sarcomas TC268 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530499,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168582,qualitative,,6089472,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : sarcomas TC71 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530500,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168585,qualitative,,6089475,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : thyroid cancer ARO cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound significantly suppressed serum-stimulated increase of total population of viable tumor cells in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530501,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168600,qualitative,,6089490,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : thyroid carcinoma ARO cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530502,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168554,qualitative,,6089444,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : thyroid carcinoma BHP-10 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530503,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168589,qualitative,,6089479,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : thyroid carcinoma BHP-17 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530504,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168605,qualitative,,6089495,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : thyroid carcinoma BHP-2 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530505,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168593,qualitative,,6089483,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : thyroid carcinoma FRO cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530506,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168556,qualitative,,6089446,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : thyroid carcinoma SW579 cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530507,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168591,qualitative,,6089481,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : thyroid carcinoma TT cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530508,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168619,qualitative,,6089509,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : thyroid carcinoma WRO cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530509,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168547,qualitative,,6089437,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : WM-WSU (Waldenstrom's Macroglobulinemia) lymphomas cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530510,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168543,qualitative,,6089433,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Target : peripheral blood B-cells,Cytotoxic,,,,,,,,,,,,,,,,,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,,,2019/06/17,
52530511,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168558,qualitative,,6089452,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806798,SW480 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530512,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168559,qualitative,,6089455,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806802,HL-60(TB) cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530513,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168560,qualitative,,6089454,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806801,LNCaP cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530514,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168561,qualitative,,6089459,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806805,ZR-75-1 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530515,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168562,qualitative,,6089460,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806807,NCI-H929 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530516,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168623,qualitative,,6089515,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 9 : In vitro anti-proliferative activity of NVP-AEW541 against a panel of Multiple Myeloma cell lines To evaluate the degree to which inhibition of IGF-IR function can suppress the ability of serum (which contains IGFs) to stimulate proliferation of MM cell lines, an MTT colorimetric survival",Cytotoxic,1806807,NCI-H929 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530517,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168563,qualitative,,6089450,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806796,L-363 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530518,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168624,qualitative,,6089513,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 9 : In vitro anti-proliferative activity of NVP-AEW541 against a panel of Multiple Myeloma cell lines To evaluate the degree to which inhibition of IGF-IR function can suppress the ability of serum (which contains IGFs) to stimulate proliferation of MM cell lines, an MTT colorimetric survival",Cytotoxic,1806796,L-363 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530519,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168599,qualitative,,6089489,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 12: NVP-AEW541 selectively impairs the survival of primary MM cells, as opposed to bone marrow stromal cells To assess whether MM cells are more susceptible to inhibition of IGF-IR signaling, than normal cells in their immediate environment, primary MM cells, normal bone marrow stromal cells",Cytotoxic,1806792,BMSC cell line,,,,,,,,,,,,,,,,,,,Not active,,,,1,"compound is ""Non Active""",,,,2018/11/16,,,2019/06/17,
52530520,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168564,qualitative,,6089451,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806797,MDA-MB-231 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530521,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168565,qualitative,,6089456,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806803,U266B1 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530522,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168625,qualitative,,6089514,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 9 : In vitro anti-proliferative activity of NVP-AEW541 against a panel of Multiple Myeloma cell lines To evaluate the degree to which inhibition of IGF-IR function can suppress the ability of serum (which contains IGFs) to stimulate proliferation of MM cell lines, an MTT colorimetric survival",Cytotoxic,1806803,U266B1 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530523,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168566,qualitative,,6089449,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806795,PC-3,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530524,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168567,qualitative,,6089453,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806800,MCF-7 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530525,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168568,qualitative,,6089448,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806794,DU145 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530526,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168569,qualitative,,6089458,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806804,ACHN cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530527,,379542,21435241,MAIN,18526473,2536074,intraperitoneal administration,,,,,,,7168570,qualitative,,6089447,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,"Bioassay :  Example 3. Analysis in vitro anti-tumor activity of IGF-1R inhibitors The functional impact of specific inhibition of IGF-1 R activation in tumor cells was quantified in vitro by MTT colorimetric survival assays, to evaluate the degree to which inhibition of IGF-1R function can suppress the ability",Cytotoxic,1806793,SK-OV-3 cell line,,,,,,,,,,,,,,,,,,title compound dose-dependently inhibited serum-stimulated cell growth in cell line tested,,,,,,,,,,2018/11/16,,,2018/11/22,
52530528,,379542,21435238,MAIN,18526472,2536073,oral administration,,,,,,,7168572,qualitative,,6089462,In Vitro (others),In Vitro (others),In Vitro (Efficacy),,,,Effect :   proteasome activity; inhibition of,,,,,,,,3844683,,Proteasome,,Wild,Proteasome:Wild,Proteasome:Wild,Proteasome,Target,Non Transfected,,,,"title compound inhibited proteasome function, measured as chemotryptic activity, in primary MM cells",,,,,,,,,,2018/11/16,Proteasome,,2018/11/22,
52530529,,379542,21435242,,20351333,,,,,,,,,7168646,IC50,,6089536,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against serum-induced proliferation of human ARK tumor cell line; Range is 0.1-0.5 uM,,1806819,ARK cell line,,,,human,,,,,,,,,,,human,,,,=,0.5,,µM,6.3,result normalized in M; pAur = -log(value),,,,2018/11/16,,1,2020/03/17,
52530530,,379542,21435242,,20351333,,,,,,,,,7168633,IC50,,6089523,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against serum-induced proliferation of human L363 tumor cell line; Range is 0.1-0.5 uM,,1806809,L-363 cell line,,,,human,,,,,,,,,,,human,,,,=,0.5,,µM,6.3,result normalized in M; pAur = -log(value),,,,2018/11/16,,1,2020/03/17,
52530531,,379542,21435242,,20351333,,,,,,,,,7168660,IC50,,6089550,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against serum-induced proliferation of human MM-1S-TR13 tumor cell line; Range is 0.1-0.5 uM,,1806827,MM1.S cell line,,,,human,,,,,,,,,,,human,,,,=,0.5,,µM,6.3,result normalized in M; pAur = -log(value),,,,2018/11/16,,1,2020/03/17,
52530532,,379542,21435242,,20351333,,,,,,,,,7168628,IC50,,6089518,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity of the compound against insulin receptor (INSR),,1806838,,,,,,3844688,,Insulin receptor,,Wild,Insulin receptor:Wild,Insulin receptor:Wild,Insulin receptor,,,,,,,=,2.8,,µM,5.55,result normalized in M; pAur = -log(value),,,,2018/11/16,Insulin receptor,1,2020/03/17,
52530533,,379542,21435245,,25733585,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530534,,379542,21435246,,25733640,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530535,,379542,21435247,,25733642,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530536,,379542,21435248,,25733646,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530537,,379542,21435249,,25733649,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530538,,379542,21435250,,25733650,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530539,,379542,21435251,,25733652,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530540,,379542,21435252,,25733654,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530541,,379542,21435253,,25733656,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530542,,379542,21435254,,25733658,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530543,,379542,21435255,,25733664,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530544,,379542,21435256,,25733665,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530545,,379542,21435257,,25733666,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530546,,379542,21435258,,25733667,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530547,,379542,21435259,,25733668,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530548,,379542,21435260,,25733669,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530549,,379542,21435261,,25733670,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530550,,379542,21435262,,25733671,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530551,,379542,21435263,,25733672,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530552,,379542,21435264,,25733673,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530553,,379542,21435265,,25733674,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530554,,379542,21435266,,25733675,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530555,,379542,21435267,,25733676,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530556,,379542,21435268,,25733678,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530557,,379542,21435269,,25733679,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530558,,379542,21435270,,25733681,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530559,,379542,21435271,,25733682,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530560,,379542,21435272,,25733685,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530561,,379542,21435243,,24270730,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530562,,379542,21435273,,25733689,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530563,,379542,21435274,,25733692,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530564,,379542,21435275,,25733693,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530565,,379542,21435276,,25733695,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530566,,379542,21435277,,25733697,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530567,,379542,21435278,,25733699,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530568,,379542,21435279,,25733700,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530569,,379542,21435280,,25733706,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530570,,379542,21435281,,25733709,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530571,,379542,21435282,,25733711,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530572,,379542,21435283,,25733712,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530573,,379542,21435284,,25733717,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530574,,379542,21435285,,25733718,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530575,,379542,21435286,,25733720,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530576,,379542,21435287,,25733725,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530577,,379542,21435288,,25733728,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
52530578,,379542,21435289,,25733732,,,,,,,,,7168634,qualitative,,6089524,,Inhibitory activity,In Vitro (Efficacy),,,Inhibitor,Inhibitory activity against insulin-like growth factor-1 receptor (IGF1R),,1806838,,,,,,3844686,,Insulin-like growth factor 1 receptor,,Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor:Wild,Insulin-like growth factor 1 receptor,,,,,,,Not Published,,,,,,,,,2018/11/16,Insulin-like growth factor 1 receptor,1,2018/11/22,
